靶向C-X-C趋化因子受体4的放射性配体治疗用于晚期T细胞淋巴瘤患者
本文报告4例晚期、经多线治疗且复发的T细胞淋巴瘤患者,在无其他合适治疗选择时接受CXCR4靶向PET及治疗前剂量学评估,随后行CXCR4靶向放射性配体治疗联合异基因(3/4,75%)或自体(1/4,25%)造血干细胞移植。治疗前剂量学显示淋巴瘤吸收剂量最高达33.2 Gy;除1例出现肿瘤溶解综合征伴一过性3级肾功能衰竭外,治疗期间未见急性毒性、过敏反应或其他不良事件;1例在放射性配体治疗后16天死于败血症。作者认为,对于晚期、经多线治疗的T细胞淋巴瘤,CXCR4靶向放射性配体治疗可能作为造血干细胞移植前的有效预处理治疗,并可产生显著的抗淋巴瘤活性。
要点
- 4例晚期经多线治疗复发的T细胞淋巴瘤患者接受CXCR4靶向放射性配体治疗联合异基因(75%)或自体(25%)造血干细胞移植。
- 治疗前剂量学显示淋巴瘤吸收剂量最高达33.2 Gy;1例出现肿瘤溶解综合征伴一过性3级肾功能衰竭,1例在治疗后16天死于败血症。
- 3例可评估患者中1例部分缓解(33.3%)、2例完全代谢缓解(66.7%);中位无进展生存期7个月(范围4-25个月)。
核心结论
- 对于晚期、经多线治疗的T细胞淋巴瘤,CXCR4靶向放射性配体治疗可能作为造血干细胞移植前的有效预处理治疗,并可产生显著的抗淋巴瘤活性,在部分病例中带来显著缓解。
研究设计与样本
- 本文为病例系列,纳入4例晚期、经多线治疗且复发的T细胞淋巴瘤患者(2男2女,中位年龄50岁),无其他合适治疗选择。
- 患者先接受CXCR4靶向PET及治疗前剂量学评估,随后接受CXCR4靶向放射性配体治疗联合异基因(3/4,75%)或自体(1/4,25%)造血干细胞移植;1例还接受了靶向CD66的放射免疫治疗以增强疗效。
- 研究考察安全性、最佳疗效、无进展生存期和总生存期。
主要发现
- 治疗前剂量学显示,CXCR4靶向放射性配体治疗对淋巴瘤的吸收剂量最高达33.2 Gy。
- 除1例出现肿瘤溶解综合征并伴一过性3级肾功能衰竭外,治疗期间未记录到急性毒性、过敏反应或其他不良事件。
- 1例发生败血症并于放射性配体治疗后16天死亡,其余3例(75%)实现植入。
- 随访中,3例可评估患者里1例(33.3%)达部分缓解,另2例(66.7%,其中1例另接受放射免疫治疗)达完全代谢缓解;中位无进展生存期为7个月(范围4-25个月)。
- 中位随访54个月(范围4-56个月)后,截至删失日期3例患者仍存活。
关键数值与推荐
- 淋巴瘤吸收剂量最高达33.2 Gy,来自CXCR4靶向放射性配体治疗的治疗前剂量学。
- 中位无进展生存期7个月(范围4-25个月);中位随访54个月(范围4-56个月)。
- 4例中异基因造血干细胞移植3例(75%)、自体造血干细胞移植1例(25%);其余3例(75%)实现植入。
临床怎么用
- 作者认为,对于晚期、经多线治疗的T细胞淋巴瘤,CXCR4靶向放射性配体治疗可能作为造血干细胞移植前的有效预处理治疗。
局限性
- 本文为病例系列,仅纳入4例患者,样本量小。
- 原文结论使用「may serve」「can cause」,提示需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
C-X-C motif chemokine receptor 4 (CXCR4)-targeted radioligand therapy (RLT) has already been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell lymphoma. We present a series of patients with advanced T-cell lymphoma (TCL) who were scheduled for CXCR4-directed therapy as a conditioning regimen, followed by hematopoietic stem cell transplantation (HSCT). Methods: Four patients with advanced, heavily pretreated, and relapsed TCL (2 men, 2 women; median age, 50 y) without suitable alternative therapeutic options underwent CXCR4-directed PET and pretherapeutic dosimetry. We then conducted CXCR4-targeted RLT in combination with allogeneic (3/4, 75%) or autologous (1/4, 25%) HSCT. One patient also underwent radioimmunotherapy targeting CD66 to enhance therapeutic efficacy. We investigated safety, best response, progression-free survival, and overall survival. Results: Pretherapeutic dosimetry indicated lymphoma-absorbed doses of up to 33.2 Gy from CXCR4-targeted RLT. Except for 1 patient who developed tumor lysis syndrome along with transient grade 3 kidney failure, no acute toxicity, allergic reactions, or other adverse events were recorded during therapy. One patient developed septicemia and subsequently died 16 d after RLT, whereas engraftment was achieved in the remaining 3 patients (75%). During follow-up, a partial response was recorded in 1 of 3 patients (33.3%) and a complete metabolic response in the other two (66.7%, with 1 patient also receiving additional radioimmunotherapy). Median progression-free survival was 7 mo (range, 4-25 mo). After a median follow-up of 54 mo (range, 4-56 mo), 3 patients were still alive at the date of censoring. Conclusion: For advanced, heavily pretreated TCL, CXCR4-directed RLT may serve as an effective conditioning therapy before HSCT and can cause substantial antilymphoma activity, leading to a remarkable response in selected cases.
引用
- Buck AK, Grigoleit GU, Kraus S, et al. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. J Nucl Med. 2022. PMID: 35738903. doi:10.2967/jnumed.122.264207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。